Navigation Links
Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
Date:12/5/2012

(PRWEB) December 05, 2012

Gallus BioPharmaceuticals, LLC (Gallus) announced that Mr. Joseph (Joe) Coffey has joined the company as Chief Commercial Officer to lead the sales and marketing organizations.

Joe joins Gallus at a time of accelerating growth following completion of a $20 million expansion which added development, clinical and commercial manufacturing contract services for bulk biopharmaceuticals.

“I am very excited to join the Gallus team and help it realize its vision. Gallus has the experienced staff, superior regulatory history, and cutting-edge technologies to deliver high quality, cost-effective biologics to the pharma and biotech industry. Gallus combines the requisite infrastructure of “big pharma” with its unique entrepreneurial focus on delighting clients” said Joe Coffey, Chief Commercial Officer of Gallus BioPharmaceuticals.

Joe brings a wealth of proven commercial experience in Sales, Marketing, Sales Force Effectiveness, and Key Account Management. Prior to joining Gallus, Joe was the Vice President, Sales for the BioPharma Solutions franchise within Baxter International Inc., providing contract manufacturing services to pharmaceutical and biotech clients. In this role, Joe led the global strategic accounts management team and developed relationships that helped establish Baxter as a globally recognized leader in contract fill/finish.

Prior to joining Baxter in 2008, Joe served the Diagnostic, Health Systems, and International business units at Abbott, Inc. for nearly two decades in a variety of progressive commercial leadership roles.

Joe also serves as a member of the Board of Directors for the Strategic Account Management Association. Joe has a Bachelor of Science in Economics from the University of Wisconsin-Madison.

“I am delighted to have Joe Coffey joining Gallus as our Chief Commercial Officer. Gallus is building on its 26 year experience of providing high quality process development, clinical and commercial supplies of biopharmaceuticals. The addition of Joe is an important step towards realizing our vision to be the Contract Manufacturer of choice for our industry” said Mark R. Bamforth, President and CEO of Gallus BioPharmaceuticals.

About Gallus BioPharmaceuticals
Gallus BioPharmaceuticals is a leading contract manufacturing company offering exceptional contract services to its clients. The firm, based in St. Louis, Mo., was established in 2010 and acquired a world-class commercial biopharmaceutical manufacturing facility and workforce from Johnson & Johnson/Centocor division in 2011. In addition to process development and clinical supply services, Gallus currently produces two commercial products that are distributed globally. The St. Louis facility has been inspected by every major regulatory body worldwide. For additional information on biopharmaceutical contract development and manufacturing services, visit http://www.gallusbiopharma.com, email info(at)gallusbiopharma(dot)com or call directly at (314) 426-5000.

Read the full story at http://www.prweb.com/releases/2012/12/prweb10198914.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
3. Mangrove Partners Agrees to Support Amended Transaction Between Nabi Biopharmaceuticals and Biota Holdings
4. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
5. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
6. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
7. Global Biopharmaceuticals Market 2011-2015
8. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
9. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
10. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , February 21, 2017 Scientists ... for Adoption by Plastic Industry  ... STEER, creator of ... materials in the fields of plastics, pharmaceuticals, food and nutraceuticals, ... Merck, a leading science & technology company, on creating ...
(Date:2/21/2017)... DUBLIN , Feb 21, 2017 Research ... & Biopolymers Market Analysis & Trends - Industry Forecast to 2025" ... ... to grow at a CAGR of around 12.8% over the next ... This industry report analyzes the market estimates and forecasts for all ...
(Date:2/20/2017)... , Feb. 20, 2017 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) ... and CEO and Fabrice Orecchioni, the company,s COO, has been named ... over the past four years, Fabrice has overseen the construction, start-up ... and the management of the Mitsui JV.  Fabrice has also ... proposed China JV. ...
(Date:2/20/2017)... NEW YORK , Feb. 20, 2017 This ... Thousand by the following Product Types: Xylanase, Amylase, Cellulase, and ... Canada , Japan , ... Latin America , and Rest of World. ... Annual estimates and forecasts are provided for the ...
Breaking Biology Technology:
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/8/2017)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its quarter and year ended December 31, 2016. ... million compared to $6.9 million in the same quarter last ... $0.6 million compared to $2.6 million in the fourth quarter ... was $0.5 million, or $0.02 per diluted share, which compares ...
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
Breaking Biology News(10 mins):